Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
about
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Novel delivery approaches for cancer therapeutics.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing miceCurative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.Gene therapy and imaging in preclinical and clinical oncology: recent developments in therapy and theranostics.The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.The increasingly anti-tumor effect of a colonic carcinoma DNA vaccine carrying HER2 by the adjuvanticity of IL-12.
P2860
Q26775030-3AD3ECBD-F8D4-417A-BCE1-9707C3B8EE6EQ30368171-B3153EA2-F5BD-4A90-8C2D-11B3F7E34464Q34020594-A7C308D3-7B00-46E2-9612-37A3A37B6125Q34059457-75C0ACE4-4134-46A7-9E61-C9EAA8CC172AQ35153121-BF551C4C-961E-45E5-8768-5498CCBB7D9BQ36393363-C3D04B22-F8DA-453E-9E84-33309A31DA8EQ37709761-E0E737BC-7BFD-401F-8EF3-8C6FA15DA85AQ38297124-195063A4-9853-43A0-91F2-58B88B823322Q38598702-52810B74-6E0F-40DB-A94D-CB092066E1B2Q38657642-794C8809-AB64-49ED-BC8E-DF27987F5BD8Q47995689-DB08AF9E-D2CE-44FD-9B7F-15D97151F120
P2860
Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@en
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@nl
type
label
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@en
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@nl
prefLabel
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@en
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@nl
P2093
P2860
P356
P1476
Oncolytic viral therapy with a ...... tor for murine ovarian cancer.
@en
P2093
Chenhong Luo
Fumi Goshima
Maki Kamakura
Shinichi Esaki
Yukihiro Nishiyama
P2860
P304
P356
10.1002/IJC.28631
P577
2013-12-02T00:00:00Z